P1.12B.03 Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK+ NSCLC from the ALTA-1L Trial

M.-J. Ahn, A. Delmonte, S. Ghosh,M. Hochmair, T.-Y. Yang, J.C.-H. Yang, J.-Y. Han,K. Holmskov Hansen, Y. Wu, Y. Wan,H.M. Lin, J. Kretz, B. Hupf, A.M. Kurec,E.N. Churchill,R.J. Fram, C.J. Cabasag, V. Goriya, Y. Zhao, E. Gemmen

Journal of Thoracic Oncology（2024）

Cited 0|Views0

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined